This article is more than 5 years old. Information may no longer be current.

Brachytherapy may be successful in failed cases of anti-VEGF therapy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FORT LAUDERDALE, Fla. — Epimacular brachytherapy should be considered as an alternative in patients unresponsive to anti-VEGF treatments, a poster presented here said.

In the presentation, lead author Adiel Barak, MD, and colleagues said at the Association for Research in Vision and Ophthalmology meeting that during 4 months of follow-up of 15 patients who underwent their epimacular brachytherapy protocol, there was no case of severe visual loss, and three patients improved by at least one line on the Snellen chart.

In the study protocol, 23-gauge pars plana vitrectomy was performed, 24 Gy of brachytherapy was applied using an intraocular strontium-90 applicator (NeoVista) for 4 minutes, and 1.25 mg of Avastin (bevacizumab, Genentech) was injected. The study was a prospective, nonrandomized, single-center case series.

There were no intraoperative complications or technical difficulties.

"Longer follow-up is needed to evaluate efficacy and recognition of patients, which can take advantage of combined radiation and anti-VEGF therapy," the authors said.

• Disclosure: Dr. Barak has financial relationships with NeoVista, Ora Bio and BioLineRx.